📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Neuland Labs Q4 FY26 PAT Surges 666% YoY to Rs 212.5 Cr; EBITDA Margins Hit 40.5%
Neuland Laboratories reported an exceptional Q4 FY26 performance with total income rising 134.9% YoY to Rs 788.7 crore. Profit After Tax (PAT) witnessed a massive jump of 666.3% YoY to Rs 212.5 crore, driven by significant operating leverage. EBITDA margins expanded drastically by 2,316 bps YoY to reach 40.5%, reflecting a shift towards high-value molecules. The company ended the full year FY26 with a total income of Rs 2,053.1 crore and EBITDA of Rs 603.4 crore.
Key Highlights
Q4 FY26 Total Income grew 134.9% YoY to Rs 788.7 crore and 76.1% QoQ.
EBITDA for the quarter surged 448.6% YoY to Rs 319.4 crore with margins expanding to 40.5%.
Net Profit (PAT) increased by 666.3% YoY to Rs 212.5 crore compared to Rs 27.7 crore in Q4FY25.
Full year FY26 total income stood at Rs 2,053.1 crore with EBITDA at Rs 603.4 crore.
Strategic investments in Peptide Manufacturing and a new R&D center are progressing as planned for future growth.
👀 What to Watch
The massive margin expansion and triple-digit profit growth indicate a strong shift in product mix or high-value CMS execution; investors should hold while monitoring the sustainability of these 40%+ EBITDA margins.
Neuland Labs FY26 Revenue Grows 37% to ₹2,053 Cr; Q4 PAT Surges 666% YoY
Neuland Laboratories reported a stellar performance for FY26, with total income rising 37.1% YoY to ₹2,053.1 crore. The growth was primarily driven by the CMS (Contract Manufacturing Solutions) segment, which saw significant scale-up in commercial molecules, especially in Q4 where total income reached ₹788.7 crore. EBITDA margins for the full year expanded by 650 bps to 29.4%, while Q4 margins hit a record 40.5%. The company remains net debt-free with a cash surplus of ₹156.8 crore and is aggressively investing in future growth through a new R&D center and peptide manufacturing facilities.
Key Highlights
FY26 Total Income grew 37.1% YoY to ₹2,053.1 crore, while Q4FY26 income spiked 134.9% to ₹788.7 crore.
Full-year EBITDA rose 76% to ₹603.4 crore with margins improving to 29.4%; Q4 EBITDA margin reached a record 40.5%.
Q4FY26 PAT surged 666.3% YoY to ₹212.5 crore, driven by high-margin commercial molecules in the CMS segment.
The company maintained a negative net debt position of ₹(156.8) crore as of March 31, 2026.
Capex outflow of ₹397 crore in FY26 was utilized for a new 140,000 sq. ft. R&D center and peptide manufacturing capabilities.
👀 What to Watch
Investors should focus on the company's successful transition of CMS molecules from clinical to commercial stages, which is significantly boosting margins. While the 40% Q4 margin may be exceptional, the structural shift toward high-value CDMO projects makes the stock a strong long-term play in the API space.
Neuland Labs Q4FY26 PAT Surges 666% to Rs 212.5 Cr; EBITDA Margins Expand to 40.5%
Neuland Laboratories reported an exceptional performance for Q4FY26, with total income growing 134.9% YoY to Rs 788.7 crore. Profitability saw a massive jump as PAT increased by 666.3% YoY to Rs 212.5 crore, driven by significant margin expansion. EBITDA margins improved by 2316 bps YoY to reach 40.5%, reflecting a shift towards high-value molecules and execution discipline. The company is also investing in peptide manufacturing and a new R&D center to sustain long-term growth beyond the current horizon.
Key Highlights
Total Income for Q4FY26 rose 134.9% YoY to Rs 788.7 crore compared to Rs 335.8 crore in Q4FY25
EBITDA grew by 448.6% YoY to Rs 319.4 crore, with margins expanding from 17.3% to 40.5%
Net Profit (PAT) skyrocketed 666.3% YoY to Rs 212.5 crore from Rs 27.7 crore in the previous year
Full-year FY26 Total Income reached Rs 2,053.1 crore with an EBITDA of Rs 603.4 crore
Management highlighted strong visibility from commercial molecules and ongoing investments in Peptide Manufacturing
👀 What to Watch
The stock is likely to react very positively to the massive margin expansion and profit growth. Investors should monitor the sustainability of these high margins and the progress of the new R&D and peptide facilities during the earnings call.
Neuland Labs Declares ₹34 Dividend and Announces ₹143.4 Cr Capacity Expansion
Neuland Laboratories has recommended a final dividend of ₹34 per share (340%) for FY 2025-26, with the record date set for July 24, 2026. Alongside the annual results, the company announced a major capacity expansion at its Unit 1 facility, adding 120.5 KL to the existing 256 KL capacity. This expansion requires an investment of ₹143.4 crores, funded via internal accruals and debt, to be completed within 12-18 months. The board also appointed Dr. Mauricio Futran as an Additional Director to strengthen the leadership team.
Key Highlights
Recommended final dividend of ₹34 per equity share (340% of face value) for FY 2025-26.
Proposed capacity addition of 120.5 KL at Unit 1, representing a ~47% increase over current 256 KL capacity.
Investment of ₹143.4 crores planned for expansion to meet high current utilization of 91%.
Expansion project timeline estimated at 12 to 18 months using internal accruals and borrowings.
Record date for dividend eligibility fixed as July 24, 2026, with AGM on August 4, 2026.
👀 What to Watch
Investors should view the high dividend and significant capacity expansion as signs of strong financial health and growth visibility. The 91% utilization rate justifies the capex, making this a positive development for long-term holders.
Neuland Labs Recommends ₹34 Dividend and Announces ₹143.4 Cr Capacity Expansion
Neuland Laboratories has approved its audited financial results for FY 2025-26 and recommended a substantial final dividend of ₹34 per share (340%). To address high utilization levels of 91%, the company is investing ₹143.4 crores to expand its Unit 1 capacity by 120.5 KL, representing a nearly 47% increase in that unit's volume. The expansion is expected to be completed within 12-18 months and will be funded through internal accruals and debt. Additionally, the board has appointed Dr. Mauricio Futran as an Additional Director to strengthen its leadership team.
Key Highlights
Recommended a final dividend of ₹34 per equity share (340%) for the financial year 2025-26.
Announced a ₹143.4 crore capacity expansion at Unit 1 (Bonthapally) to add 120.5 KL to the existing 256 KL.
Current capacity utilization at Unit 1 is at 91%, signaling a strong need for the proposed expansion.
The expansion project is scheduled for completion within a 12 to 18-month timeframe.
Fixed July 24, 2026, as the record date for the final dividend eligibility.
👀 What to Watch
The significant capacity expansion and high utilization rates indicate strong demand visibility for Neuland's API business. Investors should view the substantial dividend and growth-oriented capex as signs of management's confidence in long-term cash flows.
Saharsh Davuluri Appointed CEO & MD; Neuland Labs to Expand CDMO & Peptide Capacity
Neuland Laboratories has appointed Saharsh Davuluri as CEO & MD to lead its next growth phase, focusing on New Chemical Entities (NCE) and peptides. The company has successfully tripled its contract services revenue over the last three years and currently manages over 20 commercial contracts. Future growth is backed by a four-phase expansion of peptide capacity and a doubling of process development capabilities. The leadership transition sees former CEO Sucheth Davuluri move to Executive Vice Chairman, ensuring management continuity.
Key Highlights
Contract services revenues tripled during the last 3 years, driven by a shift toward NCE-focused CDMO work.
Committed to a four-phase expansion of commercial peptide capacity and doubling of process development capabilities.
Currently operates 3 US FDA-inspected facilities with 1218 KL of total installed capacity.
The company manages over 20 commercial contracts and has filed over 1000 DMFs globally.
Strategic goal set to become one of the world’s top five API-focused CDMOs over the next decade.
👀 What to Watch
Investors should view this as a positive succession that reinforces the company's high-margin CDMO strategy. Monitor the execution of the peptide capacity expansion and the conversion of the NCE pipeline into commercial revenue over the next 12-24 months.
Neuland Labs Q3FY26 Revenue Up 11.4% to ₹447.8 Cr; EBITDA Margin Dips to 19%
Neuland Laboratories reported an 11.4% YoY increase in total income to INR 447.8 crores for Q3FY26, with the CMS (CDMO) segment contributing over 50% of revenue. EBITDA margins compressed to 19% from previous highs, primarily due to a shift in product mix and a one-time INR 10 crore impact from labor codes. Despite a significant 9-month capex of INR 254 crores, the company maintains a strong net cash position of INR 202.6 crores. Management noted that the absence of a specific high-margin CMS product shipment and delays in Paliperidone contributed to the quarterly margin dip.
Key Highlights
Total income grew 11.4% YoY to INR 447.8 crores, driven by commercial CMS projects.
EBITDA margin stood at 19%; adjusted for a INR 10 crore labor code impact, the margin would be 21%.
9-month gross margin remains healthy at 56% compared to 55% in the previous year.
Significant 9-month capex of INR 254 crores funded largely through internal accruals and customer advances.
Working capital cycle stretched to 145 days due to higher inventories and uneven delivery flows.
👀 What to Watch
Investors should look past the quarterly margin volatility and focus on the successful ramp-up of expanded CMS capacity in Unit 3. The company's transition toward complex molecules and peptides remains the primary long-term value driver.
Neuland Labs Q3FY26 Results: PAT Drops 60.2% YoY to Rs 40.4 Cr as Margins Contract
Neuland Laboratories reported a challenging Q3FY26 with a significant 60.2% YoY decline in Profit After Tax (PAT) to Rs 40.4 crore. While Total Income grew 11.4% YoY to Rs 447.8 crore, it fell 13.2% on a sequential basis. The company faced severe margin pressure, with EBITDA margins contracting to 19.0% from 30.4% in the previous quarter, driven by an unfavorable product mix and higher operating expenses. Management remains focused on long-term investments despite the current subdued profitability.
Key Highlights
Total Income for Q3FY26 reached Rs 447.8 crore, up 11.4% YoY but down 13.2% QoQ.
EBITDA fell 5.9% YoY and 45.8% QoQ to Rs 85.0 crore.
EBITDA margins contracted sharply to 19.0%, down from 22.5% YoY and 30.4% QoQ.
Profit After Tax (PAT) plummeted 60.2% YoY to Rs 40.4 crore compared to Rs 101.4 crore in Q3FY25.
Management cited product mix shifts and increased operating expenses as primary reasons for subdued margins.
👀 What to Watch
Investors should exercise caution due to the sharp sequential decline in margins and profitability. It is essential to monitor management's guidance on the recovery of the product mix and the impact of ongoing investments on future earnings.
Neuland Labs Q3FY26: Revenue Grows 11% YoY, but PAT Declines 60% on Margin Pressure
Neuland Laboratories reported a mixed Q3FY26 with total income rising 11.4% YoY to ₹447.8 crore, supported by growth in the CMS and Prime segments. However, EBITDA margins contracted significantly by 350 bps to 19.0% due to an unfavorable product mix and higher operating expenses. Consequently, PAT for the quarter fell 60% YoY to ₹31.5 crore. Despite the bottom-line pressure, the company remains net debt-free with a cash surplus of ₹202.6 crore and continues to invest in R&D expansion.
Key Highlights
Total Income for Q3FY26 stood at ₹447.8 crore, up 11.4% YoY, while 9MFY26 income reached ₹1,264.4 crore.
EBITDA margin compressed to 19.0% in Q3FY26 from 22.5% in the previous year's quarter.
PAT for Q3FY26 dropped 60% YoY to ₹31.5 crore, with 9MFY26 PAT down 35% at ₹150.6 crore.
CMS segment remains robust with 98 active projects, including 19 commercial molecules and 10 in Phase-3.
Capital expenditure for 9MFY26 reached ₹254 crore, including plans for a new 140k sq. ft. R&D facility at Genome Valley.
👀 What to Watch
Investors should be cautious regarding the sharp margin contraction and PAT decline, which may lead to short-term stock price volatility. Focus on the management's ability to improve the product mix and the long-term growth potential of the expanding CMS project pipeline.
Neuland Labs Q3 FY26 PAT Drops 60% YoY to ₹40.4 Cr; EBITDA Margins Contract to 19%
Neuland Laboratories reported a mixed Q3 FY26 with total income growing 11.4% YoY to ₹447.8 crore, but profitability faced significant pressure. EBITDA fell 5.9% YoY to ₹85 crore, with margins contracting sharply to 19.0% from 22.5% a year ago due to an unfavorable product mix and higher operating expenses. Net profit saw a steep decline of 60.2% YoY to ₹40.4 crore, though the previous year's base was higher due to exceptional items. Management remains optimistic about long-term growth driven by the NCE drug substance segment and niche capabilities despite the short-term margin volatility.
Key Highlights
Total Income grew 11.4% YoY to ₹447.8 crore but declined 13.2% on a sequential (QoQ) basis.
EBITDA margins contracted by 350 bps YoY and 1,140 bps QoQ to 19.0%.
Profit After Tax (PAT) plummeted 60.2% YoY to ₹40.4 crore from ₹101.4 crore in the previous year.
Management cited unfavorable product mix and increased operating expenses as primary reasons for margin compression.
9MFY26 Total Income reached ₹1,264.5 crore with cumulative EBITDA at ₹284 crore.
👀 What to Watch
Investors should exercise caution due to the significant sequential margin compression and monitor the management's commentary on the sustainability of the current product mix. The stock may face short-term pressure until there is clarity on the recovery of EBITDA margins back toward the 25-30% range seen in previous quarters.
Neuland Labs Q3 PAT Drops 60% YoY to ₹40.57 Cr; Revenue Up 10.5% YoY
Neuland Laboratories reported a consolidated revenue of ₹439.71 crore for Q3 FY26, a 10.5% increase compared to ₹398.03 crore in the same quarter last year. However, Profit After Tax (PAT) saw a sharp decline of 60% YoY to ₹40.57 crore, down from ₹101.59 crore, partly due to a high base effect from an exceptional gain in the previous year. On a sequential basis, revenue fell 14.5% and PAT dropped 58% from Q2 FY26. Rising finance costs and manufacturing expenses further pressured margins during the quarter.
Key Highlights
Consolidated Revenue from Operations grew 10.5% YoY to ₹439.71 crore but declined 14.5% QoQ.
Net Profit (PAT) plummeted 60% YoY to ₹40.57 crore, impacted by higher operational costs and a lack of exceptional gains seen in the prior year.
Finance costs spiked to ₹6.79 crore compared to ₹2.22 crore in Q3 FY25, reflecting higher interest or debt obligations.
9M FY26 PAT stands at ₹151.33 crore, a 34.8% decrease from ₹232.30 crore in 9M FY25.
Geographically, USA and North America revenue grew to ₹191.80 crore, while India revenue saw a sharp decline to ₹91.59 crore from ₹172.07 crore in the previous quarter.
👀 What to Watch
Investors should exercise caution as the company faces significant margin pressure and a sharp sequential slowdown in revenue. Monitor management's commentary regarding the spike in finance costs and the volatility in the India segment revenue.
